1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fatal Prosthetic Valve Endocarditis Due to Aspergillus flavus in a Diabetic Patient

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aspergillus endocarditis (AE) accounts for a-quarter of all fungal endocarditis, mainly in immunocompromised hosts prior to heart-valve surgery with high mortality, even with treatment. Herein, we report a rare case of AE in a diabetic 60-year-old woman with a history of redo mitral valve prosthesis suspecious of acute endocarditis. She underwent second redo surgical mitral valve replacement in combination with mechanical aortic valve replacement. Blood cultures were negative. The explanted valve and vegetation were subjected to identification. Grown colonies were identified as Aspergillus flavus, based on conventional and molecular methods. Despite the administration of liposomal amphotericin B and improvement in her general condition shortly after initiation of therapy, the patient passed away. As AE is a late consequence of redo prosthetic valve replacement, extended follow-up, early diagnosis, repeating valve-replacement surgeries, and timely selective antifungal treatments are warranted.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Fungal endocarditis: evidence in the world literature, 1965-1995.

          We analyzed 270 cases of fungal endocarditis (FE) that occurred over 30 years. Vascular lines, non-cardiac surgery, immunocompromise and injection drug abuse are increasing risk factors. Delayed or mistaken diagnosis (82% of patients), long duration of symptoms before hospitalization (mean +/- standard deviation, 32+/-39 days) and extracardiac manifestations were characteristic. From 1988 onwards, 72% of patients were diagnosed preoperatively, compared with 43% before 1988 (P=.0001). The fungi most commonly isolated were Candida albicans (24% of patients), non-albicans species of Candida (24%), Apergillus species (24%), and Histoplasma species (6%); recently-emerged fungi accounted for 25% of cases. The mortality rate was 72%. Survival rates were better among patients who received combined surgical-antifungal treatment, were infected with Candida, and had univalvular involvement. Improvement in the survival rate (from or =4 years while on prophylactic antifungal therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Fungal endocarditis, 1995-2000.

            One hundred fifty-two cases of fungal endocarditis (FE) were identified in the English-language literature between January 1, 1995, and June 30, 2000. Although the median age of patients (44 years) was relatively young, injection drug use was identified as a risk factor in only 4.1% of cases. Other factors, including underlying cardiac abnormalities (47.3%), prosthetic valves (44.6%), and central venous catheters (30.4%), were more commonly identified as predisposing conditions and reflect the changing epidemiology of the syndrome. Unfortunately, mortality remains unacceptably high, particularly for patients with Aspergillus-related FE. Novel therapies are needed to improve patient outcomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Fungal Endocarditis

              Fungal endocarditis is a rare and fatal condition. The Candida and Aspergillus species are the two most common etiologic fungi found responsible for fungal endocarditis. Fever and changing heart murmur are the most common clinical manifestations. Some patients may have a fever of unknown origin as the onset symptom. The diagnosis of fungal endocarditis is challenging, and diagnosis of prosthetic valve fungal endocarditis is extremely difficult. The optimum antifungal therapy still remains debatable. Treating Candida endocarditis can be difficult because the Candida species can form biofilms on native and prosthetic heart valves. Combined treatment appears superior to monotherapy. Combination of antifungal therapy and surgical debridement might bring about better prognosis.
                Bookmark

                Author and article information

                Journal
                Infect Drug Resist
                Infect Drug Resist
                IDR
                idr
                Infection and Drug Resistance
                Dove
                1178-6973
                10 July 2020
                2020
                : 13
                : 2245-2250
                Affiliations
                [1 ]Department of Cardiology, Mazandaran University of Medical Sciences , Sari, Iran
                [2 ]Invasive Fungi Research Centre (IFRC), Mazandaran University of Medical Sciences , Sari, Iran
                [3 ]Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences , Sari, Iran
                [4 ]Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences , Sari, Iran
                [5 ]Antimicrobial Resistance Research Center, and Department of Infectious Diseases, Mazandaran University of Medical Sciences , Sari, Iran
                [6 ]Department of Cardiac Surgery, Cardiovascular Research Center of Mazandaran Heart Center, Mazandaran University of Medical Sciences , Sari, Iran
                [7 ]Department of Pathology, Mazandaran Heart Center, Mazandaran University of Medical Sciences , Sari, Iran
                Author notes
                Correspondence: Tahereh Shokohi Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences , Sari, IranTel +98 11 3354-3087Fax +98 11 3354-3248 Email Shokohi.tahereh@gmail.com
                Author information
                http://orcid.org/0000-0003-3094-8436
                http://orcid.org/0000-0001-7330-7749
                http://orcid.org/0000-0001-8200-1346
                http://orcid.org/0000-0002-9264-8984
                Article
                258637
                10.2147/IDR.S258637
                7360421
                32765000
                31b8a57b-d0b0-467d-8136-183d5d67d84b
                © 2020 Jalalian et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 15 May 2020
                : 26 June 2020
                Page count
                Figures: 4, References: 24, Pages: 6
                Categories
                Case Report

                Infectious disease & Microbiology
                fungal endocarditis,aspergillus,antifungal,prosthetic valve replacement

                Comments

                Comment on this article